The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody
Abstract
The specificity of cytotoxic T lymphocytes (Tc) cells is conferred by an antigen-specific receptor, Ti, which in humans is physically associated with an invariant cell-surface glycoprotein, T3. Monoclonal antibodies specific for either T3 and Ti are able to elicit a variety of T-cell responses such as lymphokine production, mitogenesis and cytotoxicity. For example, human Tc cells lyse anti-T3-expressing hybridoma cells, but not cells of other specificity, presumably because anti-T3 on the hybridoma cells binds to T3 on the Tc cells and triggers lysis. Here, we have adapted approaches used in a different cytotoxic effector system, antibody-dependent cellular cytotoxicity (ADCC), to alter the specificity of Tc cell. Studies of ADCC showed that heteroaggregates containing anti-Fc receptor (Fc gamma R) antibody cross-linked to a second antibody bind to Fc gamma R on ADCC effectors and cause them to kill target cells bearing antigen recognized by the second antibody. The present studies use anti-T3-containing heteroaggregates to re-target human Tc cells to cells for which we have appropriate antibodies, including xenogeneic tumour cells and chicken erythrocytes. These results extend previous observations on the role of T3 in triggering cytotoxicity and suggest that effector cell re-targeting could be used for in vivo treatment of neoplasms and other pathogens that express distinctive surface antigens.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The potential of using bispecific antibodies to retarget effector cells toward tumor cells was demonstrated in the 1980s 3,6,7”
From Bispecific antibodies for cancer therapy: The light at the end of the tunnel? (2009) · cites this paper as [7]
Citations
Cites
Unkeless, J. C. (1979) · The Journal of Experimental Medicine · doi:10.1084/jem.150.3.580 · Cited by 1,271
OKT3: A monoclonal anti-human T lymphocyte antibody with potent mitogenic properties
Wauwe, J. P. V., DeMay, J., & Goossens, J. G. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.125.5.2359.a · Cited by 710
OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties.
Wauwe, J. P. V., Mey, J. D., & Goossens, J. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.124.6.2708 · Cited by 582
Hybrid antibodies can target sites for attack by T cells
Staerz, U. D., Kanagawa, O., & Bevan, M. J. (1985) · Nature · doi:10.1038/314628a0 · Cited by 492
Antigen-like effects of monoclonal antibodies directed at receptors on human T cell clones.
Meuer, S. C., Hodgdon, J. C., Hussey, R. E., Protentis, J. P., Schlossman, S. F., & Reinherz, E. L. (1983) · The Journal of Experimental Medicine · doi:10.1084/jem.158.3.988 · Cited by 423
The Major Histocompatibility Compex-Restricted Antigen Receptor on T Cells
HASKINS, K. M., Kappler, J. W., & Marrack, P. (1984) · Annual Review of Immunology · doi:10.1146/annurev.iy.02.040184.000411 · Cited by 369
Shaw, S., Johnson, A. H., & Shearer, G. M. (1980) · The Journal of Experimental Medicine · doi:10.1084/jem.152.3.565 · Cited by 347
Self-citationMeuer, S. C., Acuto, O., Hercend, T., Schlossman, S. F., & Reinherz, E. L. (1984) · Annual Review of Immunology · doi:10.1146/annurev.iy.02.040184.000323 · Cited by 233
Landegren, U. D., Ramstedt, U., Axberg, I., Ullberg, M., Jondal, M., & Wigzell, H. (1982) · The Journal of Experimental Medicine · doi:10.1084/jem.155.5.1579 · Cited by 180
Kranz, D. M., Tonegawa, S., & Eisen, H. N. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.24.7922 · Cited by 177
Flagged first, then by citations
Research works printed but not linked: 2
- Huffman, R. W., Bluestone, J. A., Leo, O. & Shaw, S. J. Immun. (in the press).
- Sachs, D. H., Mayer, N. & Ozato, K. in Monoclonal Antibodies and T-Cell Hybridomas (eds Hammerling, G., Hammerling, U. & Kearny, J. F.) 95–101 (Eisevier, New York, 1981).
Cited by
Sorted by citations
Items 301–336 of 336
Chemospecificity and Cross‐Reactivity of Target Cell Recognition by Human CD56+ NK and LAK Cells
Zhu, H., Vötsch, W., Hauer, J., & Anderer, F. A. (1995) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.1995.tb03606.x · Cited by 2
Rigid crosslinking of the CD3 complex leads to superior T cell stimulation
Nelson, A. D., Wang, L., Laffey, K. G., Becher, L. R. E., Parks, C. A., Hoffmann, M. M., Galeano, B. K., Mangalam, A. K., Teixeiro, E., White, T., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1434463 · Cited by 1
Role of targeting nanoparticles for cancer immunotherapy and imaging
Wen, R. M., & Umeano, A. C. (2019) · Trends in Immunotherapy · doi:10.24294/ti.v3.i2.95 · Cited by 1
Razzo, B. M., & Garfall, A. L. (2023) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2023.19.1.46 · Cited by 1
de Leij, L., Jonge, M. W. A., ter Haar, J., Spakman, H., de Vries, E. G. E., Willemse, P. H. B., Mulder, N. H., Berendsen, H. H., Elias, M., Sibinga, C. T. S., et al. (1990) · Developments in biotherapie · doi:10.1007/978-94-011-3780-5_19 · Cited by 1
Intraperitoneal immunotherapy of cancer: A review of options for treatment
Claasen, H. H. V. R., & Eggermont, A. M. M. (1996) · Cancer treatment and research · doi:10.1007/978-1-4613-1247-5_2 · Cited by 1
George, A. J. T. (2010) · doi:10.1002/9780470688618.taw0099 · Cited by 1
A Mechanistic Dissection of Polyethylenimine Mediated Transfection of Chinese Hamster Ovary Cells
Mozley, O. L. (2013) · Cited by 1
Eisen, H. N., Liu, M. A., & Kranz, D. M. (1985) · Bioscience Reports · doi:10.1007/bf01119900 · Cited by 1
Cytolysis by Cloned Helper T Cells: Induction by Specific Antigen or by Anti‐CD3 Hybrid Antibodies
Vyakarnam, A., STRANGEWAYS, A. L., GLOVER, R. E., & Lachmann, P. J. (1988) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.1988.tb02396.x · Cited by 1
Conditions of anti-Lyt-2-mediated inhibition of TcR/CD3-induced IFN-γ secretion by a CTL clone
Guimezanes, A., & Schmitt‐Verhulst, A. (1990) · Cellular Immunology · doi:10.1016/0008-8749(90)90124-a · Cited by 1
Immunotherapy of breast cancer
Breitmeyer, J. B. (1992) · Cancer treatment and research · doi:10.1007/978-1-4615-3496-9_16 · Cited by 1
Bispecific Antibodies for the Treatment of Cancer: The Challenges of Translation
Jung, G., & Große‐Hovest, L. (2014) · Springer eBooks · doi:10.1007/978-3-319-05104-8_11
Lindhofer, H., Stanglmaier, M., Buhmann, R., Jäger, M., Klunker, D., Ruf, P., & Heß, J. (2014) · doi:10.1002/9783527682423.ch51
Chimeric Antigen Receptors – “CARs”
Petrausch, U., & Schirrmann, T. (2014) · Wiley eBooks · doi:10.1002/9783527682423.ch20
Emerging Therapeutic Concepts III: Chimeric Immunoglobulin T Cell Receptors, T‐Bodies
Schirrmann, T., & Pecher, G. (2007) · doi:10.1002/9783527619740.ch23
Antibody and cytokine studies related to chronic lymphocytic leukemia
Quinlan, N. P. (1994) · Dublin City University Open Access Institutional Repository (Dublin City University)
Koelemij, R., Hagenaars, M., Ensink, N. G., Eggermont, A. M. M., van de Velde, C. J. �., Fleuren, G. J., & Kuppen, P. J. K. (2001) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.2001.00875.x
Induction of anti-tumor immune response by bispecific monoclonal antibodies (bimAbs)
Ferrini, S., Cantoni, C., Cambiaggi, A., Chen, Q., Venzano, P., Canevari, S., COLNAGHI, M. I., & Moretta, L. (1992) · Pharmacological Research · doi:10.1016/1043-6618(92)90638-r
Immunotherapy of Colorectal Cancer
Margolin, K. A. (1994) · BioDrugs · doi:10.1007/bf03258521
Spits, H., Yssel, H., & de Vries, J. E. (1989) · International Reviews of Immunology · doi:10.3109/08830188909044776
Moskaug, J. Ø., Kotlar, H. K., & Sanner, T. (1987) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(87)90008-3
Human T Cells Targeted with Hetero‐cross‐linked Antibodies Prevent Tumor Growth in Nude Mice
Segal, D. M., Titus, J. A., Hecht, T. T., GARRIDO, M. A., Winkler, D. F., & Wunderlich, J. R. (1988) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1988.tb36377.x
Self-citationMHC Restricted Recognition by Cloned T Cells
Hodes, R. J. (1986) · International Reviews of Immunology · doi:10.3109/08830188609056604
RESPONSES WITH MONOCLONAL ANTIBODIES
Waldmann, H. (1989)
The enhancement of cytolytic activity in lymphokine activated killer cells using bispecific F(ab')2.
Azuma, A. (1991) · Journal of Nippon Medical School · doi:10.1272/jnms1923.58.663
Segal, D. M., & Jost, C. R. (1993)
Self-citationAzuma, A., & Niitani, H. (1991) · PubMed
Clinical Results of Specific Targeting Therapy Against Patients with Malignant Glioma
Hishii, M., Nitta, T., Ebato, M., Okumura, K., & Sato, K. (1996) · Springer eBooks · doi:10.1007/978-4-431-66887-9_37
Mayforth, R. D. (1993) · Elsevier eBooks · doi:10.1016/b978-0-12-481025-9.50007-2
ADME of Biologicals and New Therapeutic Modalities
Foti, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00141-9
(2006) · Kluwer Academic Publishers eBooks · doi:10.1007/1-4020-2804-0_8
Antibody-Redirected T-Cell Immunotherapy for Brain Tumors
Choi, B. D. (2014) · DukeSpace (Duke University)
Noori, M., Yazdanpanah, N., & Rezaei, N. (2024) · Figshare · doi:10.6084/m9.figshare.26615227
Bispecifics: The future of therapeutic antibodies
Davis, J. H. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00093-5
Metadata
- Authors
- Perez, P., Hoffman, R. W., Shaw, S., Bluestone, J. A., & Segal, D. M.
- Affiliations
- National Institutes of Health (US)
- Venue
- Nature
- Published
- 1985-07
- Volume
- 316
- Issue
- 6026
- Pages
- 354-356
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2065272367
- Cited by
- 337
- References
- 23
- Citations by year
- 2026: 4 · 2024: 10 · 2023: 7 · 2022: 7 · 2021: 17 · 2020: 9 · 2019: 7 · 2018: 10 · 2017: 6 · 2016: 6 · 2015: 4 · 2014: 11 · 2013: 6 · 2012: 6
- FWCI
- 22.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- cytotoxic T lymphocytes, T cell receptor, antibody-dependent cellular cytotoxicity, heteroaggregates, T cell specificity, chicken erythrocytes, T cell cytotoxicity
- MeSH terms
- Animals, Antibodies, Antibodies, Monoclonal, Antibody Specificity, Antibody-Dependent Cell Cytotoxicity, Antigens, Surface, Clone Cells, Glycoproteins, Histocompatibility Antigens, Humans, Receptors, Antigen, T-Cell, T-Lymphocytes, Cytotoxic, CD3 Complex, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review